These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34428551)

  • 1. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.
    Im E; Sim DY; Lee HJ; Park JE; Park WY; Ko S; Kim B; Shim BS; Kim SH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):1066-1075. PubMed ID: 34428551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New emerging targets in cancer immunotherapy: the role of VISTA.
    Tagliamento M; Bironzo P; Novello S
    ESMO Open; 2020 Jun; 4(Suppl 3):e000683. PubMed ID: 32554470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
    Zheng S; Zhang K; Zhang X; Xiao Y; Wang T; Jiang S
    J Med Chem; 2022 Sep; 65(18):11900-11912. PubMed ID: 36083840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VISTA: A Promising Target for Cancer Immunotherapy?
    Tagliamento M; Agostinetto E; Borea R; Brandão M; Poggio F; Addeo A; Lambertini M
    Immunotargets Ther; 2021; 10():185-200. PubMed ID: 34189130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VISTA: Coming of age as a multi-lineage immune checkpoint.
    ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
    Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
    Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
    Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.
    Huang X; Zhang X; Li E; Zhang G; Wang X; Tang T; Bai X; Liang T
    J Hematol Oncol; 2020 Jun; 13(1):83. PubMed ID: 32600443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.
    Chmiel P; Gęca K; Michalski A; Kłosińska M; Kaczyńska A; Polkowski WP; Pelc Z; Skórzewska M
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA.
    Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J
    BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VISTA expression and patient selection for immune-based anticancer therapy.
    Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
    Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
    Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
    Wang Y; Zhang H; Liu C; Wang Z; Wu W; Zhang N; Zhang L; Hu J; Luo P; Zhang J; Liu Z; Peng Y; Liu Z; Tang L; Cheng Q
    J Hematol Oncol; 2022 Aug; 15(1):111. PubMed ID: 35978433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
    Yuan L; Tatineni J; Mahoney KM; Freeman GJ
    Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
    Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():676181. PubMed ID: 34093577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.
    Noelle RJ; Lines JL; Lewis LD; Martell RE; Guillaudeux T; Lee SW; Mahoney KM; Vesely MD; Boyd-Kirkup J; Nambiar DK; Scott AM
    Front Oncol; 2023; 13():1225081. PubMed ID: 37795437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
    Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
    Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.